T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Janux Therapeutics
JANX
$986M
| $59.4M | 0.01% |
1,109,978
+950,557
| +596% | +$50.3M |
|
702
AngloGold Ashanti
AU
$48.2B
| $59.3M | 0.01% |
2,569,868
+1,045,335
| +69% | +$27.3M |
|
703
Arch Capital
ACGL
$33.5B
| $59.3M | 0.01% |
641,973
-107,941
| -14% | -$10.9M |
|
704
Exelixis
EXEL
$12.6B
| $58.8M | 0.01% |
1,766,841
-125,006
| -7% | -$4.06M |
|
705
Mirum Pharmaceuticals
MIRM
$6.05B
| $58.8M | 0.01% |
1,422,729
+138,623
| +11% | +$5.78M |
|
706
Uranium Energy
UEC
$5.57B
| $58.6M | 0.01% |
8,757,032
-33,500
| -0.4% | -$256K |
|
707
Willis Towers Watson
WTW
$31.2B
| $58.3M | 0.01% |
186,165
-15,474
| -8% | -$4.75M |
|
708
Halozyme
HALO
$11.4B
| $58.2M | 0.01% |
1,218,326
-52,195
| -4% | -$2.68M |
|
709
D.R. Horton
DHI
$41.8B
| $58.2M | 0.01% |
416,202
+4,570
| +1% | +$764K |
|
710
Vontier
VNT
$4.49B
| $58.2M | 0.01% |
1,595,092
-102,576
| -6% | -$3.79M |
|
711
Kroger
KR
$35.2B
| $58.1M | 0.01% |
949,956
+12,577
| +1% | +$738K |
|
712
InterDigital
IDCC
$8.95B
| $58M | 0.01% |
299,326
+280,030
| +1,451% | +$49M |
|
713
W.P. Carey
WPC
$16.3B
| $57.7M | 0.01% |
1,058,351
+21,954
| +2% | +$1.25M |
|
714
Procept Biorobotics
PRCT
$1.26B
| $57.5M | 0.01% |
713,856
-63,574
| -8% | -$5.43M |
|
715
Cleveland-Cliffs
CLF
$6.92B
| $56.8M | 0.01% |
6,039,638
+607,236
| +11% | +$7.32M |
|
716
IQVIA
IQV
$39.7B
| $56.7M | 0.01% |
288,512
-124,498
| -30% | -$26.3M |
|
717
Nurix Therapeutics
NRIX
$2.8B
| $56.7M | 0.01% |
3,007,327
-61,634
| -2% | -$1.41M |
|
718
Dyne Therapeutics
DYN
$4.86B
| $56.6M | 0.01% |
2,402,452
-233,841
| -9% | -$6.92M |
|
|
EDR
719
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $56.5M | 0.01% |
1,807,051
-135,077
| -7% | -$4.02M |
|
720
Teradyne
TER
$64.3B
| $55.2M | 0.01% |
438,631
-84,772
| -16% | -$10M |
|
721
Ford
F
$55.3B
| $55.1M | 0.01% |
5,570,170
-1,080,892
| -16% | -$11.5M |
|
722
Steris
STE
$23.1B
| $54.6M | 0.01% |
265,662
-119,727
| -31% | -$26.3M |
|
723
Guidewire Software
GWRE
$15.3B
| $54.6M | 0.01% |
323,846
-251,495
| -44% | -$47M |
|
724
Expro Ltd
XPRO
$2.08B
| $54.6M | 0.01% |
4,376,250
+436,411
| +11% | +$6.08M |
|
725
Xylem
XYL
$28.2B
| $54.5M | 0.01% |
469,760
-140
| -0% | -$17.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.